Pfizer Inc. to Seek to Appeal Lipitor Enantiomer Patent Ruling in the Netherlands, Company Notes That Ruling Has No Commercial Impact

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc said today that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that Pfizer’s atorvastatin enantiomer patent is invalid. The patent (EP 409,281) had been challenged by generics manufacturer Ranbaxy and expires in July 2010.